Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221960 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02221960 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 39 participants.
The verdict
NCT02221960, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.
Interventions
- BIOLOGICAL MEDI6383
- BIOLOGICAL MEDI6383 and MEDI4736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2017-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02221960
The ClinicalTrials.gov registry entry for NCT02221960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI6383 is the first listed.
NCT02221960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02221960 about?
NCT02221960 is a clinical study titled "A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors". To evaluate MEDI6383 when given alone or together with MEDI4736 in adult subjects with recurrent or metastatic solid tumors.
What is the current status of trial NCT02221960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2014-09-15. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT02221960?
The interventions under investigation include: MEDI6383 (BIOLOGICAL), MEDI6383 and MEDI4736 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02221960?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.